SARS-CoV-2 spike glycoprotein S1 N-terminal domain (S1-NTD)

The SARS-CoV-2 spike glycoprotein S1 N-terminal domain (NTD) is a prominent structural region of the viral spike protein that plays a vital role in the initial stages of infection. While the receptor-binding domain (RBD) is well-known for its interaction with the ACE2 receptor, the NTD facilitates viral attachment by binding to alternative host factors, such as sialic acids, gangliosides, and C-type lectins like L-SIGN and DC-SIGN (PubMed: 32979937, 34019810). This domain is highly immunogenic and serves as a key target for neutralizing antibodies, such as the monoclonal antibody 4A8, which can inhibit viral entry by preventing the conformational transitions required for membrane fusion (PubMed: 32555388). However, the NTD is also a major site of genetic variation, with frequent mutations and deletions observed in variants of concern (VOCs) like Alpha, Delta, and Omicron, which contribute to immune evasion and increased transmissibility (PubMed: 33607086, 34903715). Consequently, the NTD is a critical focus for the development of broad-spectrum therapeutics and next-generation vaccines aimed at overcoming viral escape. Despite its therapeutic potential, the rapid evolution of the NTD poses a significant challenge for maintaining the efficacy of monoclonal antibody treatments.

Other names

NTDS1-NTDN-terminal domain of the spike proteinSpike protein S1 subunit N-terminal domainSARS-CoV-2 S1 NTD

Neutralization of viral entry by blocking attachment to host cells or inhibiting conformational changes required for membrane fusion